{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:50:12Z","timestamp":1770216612087,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T00:00:00Z","timestamp":1291680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10620-010-1507-8","type":"journal-article","created":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T10:14:09Z","timestamp":1291630449000},"page":"564-568","source":"Crossref","is-referenced-by-count":57,"title":["The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort"],"prefix":"10.1007","volume":"56","author":[{"given":"Barham K.","family":"Abu Dayyeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules L.","family":"Dienstag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,7]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","volume":"118","author":"R Bataller","year":"2000","unstructured":"Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149\u20131156.","journal-title":"Gastroenterology"},{"key":"1507_CR2","doi-asserted-by":"crossref","first-page":"G642","DOI":"10.1152\/ajpgi.00037.2003","volume":"285","author":"R Bataller","year":"2003","unstructured":"Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642\u2013G651.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1507_CR3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI18212","volume":"112","author":"R Bataller","year":"2003","unstructured":"Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J. Nadph oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112:1383\u20131394.","journal-title":"J Clin Invest"},{"key":"1507_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0016-5085(03)00695-4","volume":"125","author":"R Bataller","year":"2003","unstructured":"Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117\u2013125.","journal-title":"Gastroenterology"},{"key":"1507_CR5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3748\/wjg.v12.i2.322","volume":"12","author":"S Yokohama","year":"2006","unstructured":"Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12:322\u2013326.","journal-title":"World J Gastroenterol"},{"key":"1507_CR6","first-page":"540","volume":"6","author":"HS Wei","year":"2000","unstructured":"Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCL(4). World J Gastroenterol. 2000;6:540\u2013545.","journal-title":"World J Gastroenterol"},{"key":"1507_CR7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/jhep.2001.28231","volume":"34","author":"H Yoshiji","year":"2001","unstructured":"Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745\u2013750.","journal-title":"Hepatology"},{"key":"1507_CR8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/gast.2001.25480","volume":"121","author":"JR Jonsson","year":"2001","unstructured":"Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148\u2013155.","journal-title":"Gastroenterology"},{"key":"1507_CR9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0168-8278(02)00307-0","volume":"37","author":"V Croquet","year":"2002","unstructured":"Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and\/or portal hypertension. J Hepatol. 2002;37:773\u2013780.","journal-title":"J Hepatol"},{"key":"1507_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0006-291X(03)01357-3","volume":"308","author":"K Kanno","year":"2003","unstructured":"Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCL(4). Biochem Biophys Res Commun. 2003;308:177\u2013183.","journal-title":"Biochem Biophys Res Commun"},{"key":"1507_CR11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1023\/B:DDAS.0000043369.88701.5b","volume":"49","author":"YH Wei","year":"2004","unstructured":"Wei YH, Jun L, Jun L. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCL4 in rats. Dig Dis Sci. 2004;49:1589\u20131594.","journal-title":"Dig Dis Sci"},{"key":"1507_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jhep.2005.02.034","volume":"43","author":"L Yang","year":"2005","unstructured":"Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol. 2005;43:317\u2013323.","journal-title":"J Hepatol"},{"key":"1507_CR13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32679","volume":"36","author":"Y Terui","year":"2002","unstructured":"Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002;36:1022.","journal-title":"Hepatology"},{"key":"1507_CR14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2007.01.017","volume":"46","author":"W Debernardi-Venon","year":"2007","unstructured":"Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G. AT1 receptor antagonist candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026\u20131033.","journal-title":"J Hepatol"},{"key":"1507_CR15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","volume":"40","author":"S Yokohama","year":"2004","unstructured":"Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222\u20131225.","journal-title":"Hepatology"},{"key":"1507_CR16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.TP.0000128913.09774.CE","volume":"78","author":"A Rimola","year":"2004","unstructured":"Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation. 2004;78:686\u2013691.","journal-title":"Transplantation"},{"key":"1507_CR17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00535-004-1523-6","volume":"40","author":"H Yoshiji","year":"2005","unstructured":"Yoshiji H, Noguchi R, Fukui H. Combined effect of an ace inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol. 2005;40:215\u2013216.","journal-title":"J Gastroenterol"},{"key":"1507_CR18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","volume":"29","author":"KE Corey","year":"2009","unstructured":"Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009;29:748\u2013753.","journal-title":"Liver Int"},{"key":"1507_CR19","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","volume":"359","author":"AM Di Bisceglie","year":"2008","unstructured":"Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429\u20132441.","journal-title":"N Engl J Med"},{"key":"1507_CR20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u2013699.","journal-title":"J Hepatol"},{"key":"1507_CR21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.23315","volume":"51","author":"JE Everhart","year":"2010","unstructured":"Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE. Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51:585\u2013594.","journal-title":"Hepatology"},{"key":"1507_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1478-3231.2009.02059.x","volume":"30","author":"E Cholongitas","year":"2010","unstructured":"Cholongitas E, Vibhakorn S, Lodato F, Burroughs AK. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation. Liver Int. 2010;30:334\u2013335.","journal-title":"Liver Int"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-010-1507-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-010-1507-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-010-1507-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:43:04Z","timestamp":1559245384000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-010-1507-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,7]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s10620-010-1507-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,7]]}}}